Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) plus palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2-eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study

Hurvitz SA, Park YH, Bardia A, Quiroga V, Lopez-Valverde V, Steinseifer J, Moore HM, Spera G, Xue C, Fasching P (2021)

Publication Type: Conference contribution

Publication year: 2021

Journal

Annals of Oncology Elsevier

Publisher: ELSEVIER

City/Town: AMSTERDAM

Pages Range: S1285-S1286

Conference Proceedings Title: ANNALS OF ONCOLOGY

DOI: 10.1016/j.annonc.2021.08.2086

Authors with CRIS profile

Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe

Involved external institutions

University of California Los Angeles (UCLA)

United States (USA) (US) Sungkyunkwan University (SKKU)

Korea, Republic of (KR) Harvard University

United States (USA) (US) Spanish Breast Cancer Group / Grupo Español de Investigación en Cáncer de Mama (GEICAM)

Spain (ES) F. Hoffmann-La Roche Ltd

Switzerland (CH) Genentech Inc.

United States (USA) (US)

How to cite

APA:

Hurvitz, S.A., Park, Y.H., Bardia, A., Quiroga, V., Lopez-Valverde, V., Steinseifer, J.,... Fasching, P. (2021). Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) plus palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2-eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study. In ANNALS OF ONCOLOGY (pp. S1285-S1286). AMSTERDAM: ELSEVIER.

MLA:

Hurvitz, S. A., et al. "Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) plus palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2-eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study." Proceedings of the ANNALS OF ONCOLOGY AMSTERDAM: ELSEVIER, 2021. S1285-S1286.

BibTeX: Download